Function of IKKbeta in the progression and regression of liver fibrosis View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2007-2010

FUNDING AMOUNT

259312 GBP

ABSTRACT

Liver cirrhosis is the end stage of a process known as fibrosis in which the normal healthy tissues of the liver are over several years progressively replaced with non-functional scar tissue. This process leaves the liver in a state of structural and functional disorder for which the only option is replacement by transplantation to prevent death. This disease process can be caused by a wide variety of injuries including those inflicted by viruses (hepatitis C and B), alcohol, metabolic agents and autoimmune attack. Recent work in the applicants laboratory as well as in other laboratories across the world has given new hope to the treatment of liver fibrosis by demonstrating that it is a process that can be reversed. Reversibility of fibrosis is associated with the removal from the liver of a specialised cell (hepatic myofibroblast) that is responsible for production of scar tissue, however removal of these cells is very inefficient in livers that are undergoing persistent injury. In pioneering studies the applicants have shown that drugs which target a survival factor called NF-kB will promote the removal of hepatic myofibroblasts from the liver without affecting other liver cells required for healthy function. The aim of the project for which grant income is requested is to learn more about one of the key molecules that control NF-kB. This molecule known as IKKbeta is already a target for emerging anti-inflammatory drugs which may eventually offer an alternative to transplantation if we can find evidence that it plays an important role in fibrosis. The experiments that are proposed are designed to discover if loss of IKKbeta and NF-kB activities in hepatic myofibroblasts will result in reduced severity of fibrosis and enhanced rates of recovery from liver disease. The results will be used to inform colleagues in hepatology clinics as to the likely benefits of the use of IKKbeta inhibitors in the treatment of liver disease patients. The results of the work will also be presented to the general public via press releases (organised through the University of Southampton and the Medical Research Council Press Offices and Websites) as well as in the form of public lectures and publication of data in high quality scientific journals. Technical Summary Liver fibrosis involves progressive replacement of liver tissue with scar tissue in response to chronic injury (alcohol, HCV, fat etc) and leads to the end-stage disease of cirrhosis. In the past 5 years, clinical and experimental studies have revealed a new paradigm, that fibrosis can regress as well as progress. However, spontaneous regression is only achieved in a small number of patients that can be effectively treated for the underlying cause of liver disease and even in these cases recovery is slow and incomplete. Studies pioneered by the applicants shows that stimulation of apoptosis of scar producing hepatic myofibroblasts (HM) accelerates the rate at which experimental fibrosis is spontaneously resolved. These studies identified NF-kB and its regulatory IkappaKinases (IKK) complex as critical controllers of HM apoptosis. Inhibition of NF-kB/IKK activity is associated with elevated rates of HM apoptosis and rapid recovery from fibrosis. The overarching aim of the current proposal is to determine the role played by the IKKbeta component of the IKK complex and to develop a highly specific inhibitor of IKKbeta action in HM. The role of IKKbeta in both the progressive and regressive phases of fibrosis will be investigated using a mouse in which the IKKbeta gene can be deleted at will and selectively in fibroblasts and myofibroblasts. Mice in which the IKKbeta allele is flanked by loxP sites will be crossed with mice in which Cre is under the transcriptional control of the alpha2 (I) collagen enhancer and post-translational control by Tamoxifen providing regulated and cell-specific knockout of IKKbeta expression. Importantly, this system will enable the fibrogenic role of IKKbeta to be studied independently from its pro-inflammatory function in the injured liver. The mice will be used in models of fibrogenesis (CCl4 injury) and recovery from fibrosis (following chronic injury with CCl4). Histological (Sirius Red for collagen I/III and alphaSMA for numbers of HM) and biochemical (qRT-PCR for fibrogenic markers, hydroxyproline and MMP activity assays). We anticipate that loss of IKKbeta will be associated with prevention of fibrosis and improved rates of recovery from fibrosis. Work in the second part of the proposal will address the way in which IKKbeta regulates NF-kB which from previous work and pilot data appears to operate via phosphorylation of the p65 subunit of NF-kB. In addition a specific peptide inhibitor of IKKbeta-mediated p65 phosphorylation will be tested for its ability to inhibit NF-kB, promote apoptosis and stimulate recovery from fibrosis. More... »

URL

http://gtr.rcuk.ac.uk/project/71B673FF-09A0-4580-B6ED-EACB128618C4

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "GBP", 
      "type": "MonetaryAmount", 
      "value": "259312"
    }, 
    "description": "Liver cirrhosis is the end stage of a process known as fibrosis in which the normal healthy tissues of the liver are over several years progressively replaced with non-functional scar tissue. This process leaves the liver in a state of structural and functional disorder for which the only option is replacement by transplantation to prevent death. This disease process can be caused by a wide variety of injuries including those inflicted by viruses (hepatitis C and B), alcohol, metabolic agents and autoimmune attack. Recent work in the applicants laboratory as well as in other laboratories across the world has given new hope to the treatment of liver fibrosis by demonstrating that it is a process that can be reversed. Reversibility of fibrosis is associated with the removal from the liver of a specialised cell (hepatic myofibroblast) that is responsible for production of scar tissue, however removal of these cells is very inefficient in livers that are undergoing persistent injury. In pioneering studies the applicants have shown that drugs which target a survival factor called NF-kB will promote the removal of hepatic myofibroblasts from the liver without affecting other liver cells required for healthy function. The aim of the project for which grant income is requested is to learn more about one of the key molecules that control NF-kB. This molecule known as IKKbeta is already a target for emerging anti-inflammatory drugs which may eventually offer an alternative to transplantation if we can find evidence that it plays an important role in fibrosis. The experiments that are proposed are designed to discover if loss of IKKbeta and NF-kB activities in hepatic myofibroblasts will result in reduced severity of fibrosis and enhanced rates of recovery from liver disease. The results will be used to inform colleagues in hepatology clinics as to the likely benefits of the use of IKKbeta inhibitors in the treatment of liver disease patients. The results of the work will also be presented to the general public via press releases (organised through the University of Southampton and the Medical Research Council Press Offices and Websites) as well as in the form of public lectures and publication of data in high quality scientific journals.\n\nTechnical Summary\nLiver fibrosis involves progressive replacement of liver tissue with scar tissue in response to chronic injury (alcohol, HCV, fat etc) and leads to the end-stage disease of cirrhosis. In the past 5 years, clinical and experimental studies have revealed a new paradigm, that fibrosis can regress as well as progress. However, spontaneous regression is only achieved in a small number of patients that can be effectively treated for the underlying cause of liver disease and even in these cases recovery is slow and incomplete. Studies pioneered by the applicants shows that stimulation of apoptosis of scar producing hepatic myofibroblasts (HM) accelerates the rate at which experimental fibrosis is spontaneously resolved. These studies identified NF-kB and its regulatory IkappaKinases (IKK) complex as critical controllers of HM apoptosis. Inhibition of NF-kB/IKK activity is associated with elevated rates of HM apoptosis and rapid recovery from fibrosis. The overarching aim of the current proposal is to determine the role played by the IKKbeta component of the IKK complex and to develop a highly specific inhibitor of IKKbeta action in HM. The role of IKKbeta in both the progressive and regressive phases of fibrosis will be investigated using a mouse in which the IKKbeta gene can be deleted at will and selectively in fibroblasts and myofibroblasts. Mice in which the IKKbeta allele is flanked by loxP sites will be crossed with mice in which Cre is under the transcriptional control of the alpha2 (I) collagen enhancer and post-translational control by Tamoxifen providing regulated and cell-specific knockout of IKKbeta expression. Importantly, this system will enable the fibrogenic role of IKKbeta to be studied independently from its pro-inflammatory function in the injured liver. The mice will be used in models of fibrogenesis (CCl4 injury) and recovery from fibrosis (following chronic injury with CCl4). Histological (Sirius Red for collagen I/III and alphaSMA for numbers of HM) and biochemical (qRT-PCR for fibrogenic markers, hydroxyproline and MMP activity assays). We anticipate that loss of IKKbeta will be associated with prevention of fibrosis and improved rates of recovery from fibrosis. Work in the second part of the proposal will address the way in which IKKbeta regulates NF-kB which from previous work and pilot data appears to operate via phosphorylation of the p65 subunit of NF-kB. In addition a specific peptide inhibitor of IKKbeta-mediated p65 phosphorylation will be tested for its ability to inhibit NF-kB, promote apoptosis and stimulate recovery from fibrosis.", 
    "endDate": "2010-02-28T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.14105.31", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2764772", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2764772"
        ]
      }, 
      {
        "name": "gtr_id", 
        "type": "PropertyValue", 
        "value": [
          "71B673FF-09A0-4580-B6ED-EACB128618C4"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "recovery", 
      "death", 
      "transcriptional control", 
      "IKKbeta action", 
      "will", 
      "applicants", 
      "hepatology clinic", 
      "cirrhosis", 
      "fibrogenic markers", 
      "NF-kB activity", 
      "HM apoptosis", 
      "rate", 
      "other liver cells", 
      "apoptosis", 
      "applicant laboratory", 
      "phosphorylation", 
      "fibrosis", 
      "system", 
      "response", 
      "only option", 
      "collagen enhancer", 
      "liver disease patients", 
      "progression", 
      "Websites", 
      "liver tissue", 
      "ability", 
      "p65 phosphorylation", 
      "end stage", 
      "Sirius Red", 
      "metabolic agents", 
      "other laboratories", 
      "small number", 
      "autoimmune attack", 
      "overarching aim", 
      "functional disorders", 
      "loss", 
      "virus", 
      "hydroxyproline", 
      "evidence", 
      "IKKbeta", 
      "specific inhibitor", 
      "cell-specific knockout", 
      "role", 
      "HCV", 
      "fibroblasts", 
      "loxP sites", 
      "drugs", 
      "important role", 
      "end-stage disease", 
      "regressive phase", 
      "high quality", 
      "key molecules", 
      "survival factor", 
      "project", 
      "pilot data", 
      "persistent injury", 
      "rapid recovery", 
      "improved rates", 
      "fibrogenesis", 
      "production", 
      "regression", 
      "replacement", 
      "proposal", 
      "results", 
      "way", 
      "process", 
      "data", 
      "hepatitis C", 
      "use", 
      "new hope", 
      "experiments", 
      "removal", 
      "chronic injury", 
      "normal healthy tissue", 
      "scientific journals", 
      "CCl4 injury", 
      "pro-inflammatory functions", 
      "number", 
      "function", 
      "Cre", 
      "IKKbeta gene", 
      "wide variety", 
      "tamoxifen", 
      "years", 
      "state", 
      "prevention", 
      "model", 
      "IKKbeta inhibitors", 
      "reversibility", 
      "addition", 
      "alternative", 
      "form", 
      "IKK", 
      "world", 
      "collagen I/III", 
      "grant income", 
      "experimental fibrosis", 
      "NF-kB", 
      "enhanced rates", 
      "MMP activity assays", 
      "likely benefit", 
      "critical controller", 
      "progressive replacement", 
      "Southampton", 
      "elevated rates", 
      "CCl4", 
      "study", 
      "work", 
      "Histological", 
      "liver", 
      "patients", 
      "post-translational control", 
      "several years", 
      "technical summary", 
      "alpha2", 
      "University", 
      "injured liver", 
      "IKK complex", 
      "liver fibrosis", 
      "alphaSMA", 
      "colleagues", 
      "publication", 
      "healthy function", 
      "second part", 
      "p65 subunit", 
      "qRT-PCR", 
      "reduced severity", 
      "alcohol", 
      "fibrogenic role", 
      "liver disease", 
      "current proposals", 
      "cells", 
      "inhibition", 
      "Medical Research Council Press Offices", 
      "experimental study", 
      "scar tissue", 
      "transplantation", 
      "anti-inflammatory drugs", 
      "scar", 
      "myofibroblasts", 
      "liver cirrhosis", 
      "non-functional scar tissue", 
      "public lectures", 
      "hepatic myofibroblasts", 
      "specific peptide inhibitor", 
      "IKKbeta component", 
      "stimulation", 
      "underlying cause", 
      "treatment", 
      "IKKbeta allele", 
      "disease process", 
      "injury", 
      "molecules", 
      "previous work", 
      "cases recovery", 
      "NF-kB.", 
      "IKKbeta expression", 
      "mice", 
      "general public", 
      "spontaneous regression", 
      "recent work", 
      "target", 
      "IKK activity", 
      "new paradigm", 
      "progress", 
      "press releases", 
      "aim"
    ], 
    "name": "Function of IKKbeta in the progression and regression of liver fibrosis", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.1006.7", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.1006.7", 
          "name": "Newcastle University", 
          "type": "Organization"
        }, 
        "familyName": "Mann", 
        "givenName": "Derek", 
        "id": "sg:person.01361723223.86", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01361723223.86", 
        "roleName": "PI", 
        "type": "Role"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.1006.7", 
          "name": "Newcastle University", 
          "type": "Organization"
        }, 
        "familyName": "Mann", 
        "givenName": "Jelena", 
        "id": "sg:person.0636317123.31", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.0636317123.31", 
        "roleName": "Co-PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2764772"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T11:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/gtr_projects_0.xml.gz", 
    "startDate": "2007-03-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://gtr.rcuk.ac.uk/project/71B673FF-09A0-4580-B6ED-EACB128618C4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2764772'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2764772'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2764772'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2764772'


 

This table displays all metadata directly associated to this object as RDF triples.

220 TRIPLES      19 PREDICATES      191 URIs      182 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:grant.2764772 schema:about anzsrc-for:2211
2 schema:amount N37365371ff71465fbad3586110b4f268
3 schema:description Liver cirrhosis is the end stage of a process known as fibrosis in which the normal healthy tissues of the liver are over several years progressively replaced with non-functional scar tissue. This process leaves the liver in a state of structural and functional disorder for which the only option is replacement by transplantation to prevent death. This disease process can be caused by a wide variety of injuries including those inflicted by viruses (hepatitis C and B), alcohol, metabolic agents and autoimmune attack. Recent work in the applicants laboratory as well as in other laboratories across the world has given new hope to the treatment of liver fibrosis by demonstrating that it is a process that can be reversed. Reversibility of fibrosis is associated with the removal from the liver of a specialised cell (hepatic myofibroblast) that is responsible for production of scar tissue, however removal of these cells is very inefficient in livers that are undergoing persistent injury. In pioneering studies the applicants have shown that drugs which target a survival factor called NF-kB will promote the removal of hepatic myofibroblasts from the liver without affecting other liver cells required for healthy function. The aim of the project for which grant income is requested is to learn more about one of the key molecules that control NF-kB. This molecule known as IKKbeta is already a target for emerging anti-inflammatory drugs which may eventually offer an alternative to transplantation if we can find evidence that it plays an important role in fibrosis. The experiments that are proposed are designed to discover if loss of IKKbeta and NF-kB activities in hepatic myofibroblasts will result in reduced severity of fibrosis and enhanced rates of recovery from liver disease. The results will be used to inform colleagues in hepatology clinics as to the likely benefits of the use of IKKbeta inhibitors in the treatment of liver disease patients. The results of the work will also be presented to the general public via press releases (organised through the University of Southampton and the Medical Research Council Press Offices and Websites) as well as in the form of public lectures and publication of data in high quality scientific journals. Technical Summary Liver fibrosis involves progressive replacement of liver tissue with scar tissue in response to chronic injury (alcohol, HCV, fat etc) and leads to the end-stage disease of cirrhosis. In the past 5 years, clinical and experimental studies have revealed a new paradigm, that fibrosis can regress as well as progress. However, spontaneous regression is only achieved in a small number of patients that can be effectively treated for the underlying cause of liver disease and even in these cases recovery is slow and incomplete. Studies pioneered by the applicants shows that stimulation of apoptosis of scar producing hepatic myofibroblasts (HM) accelerates the rate at which experimental fibrosis is spontaneously resolved. These studies identified NF-kB and its regulatory IkappaKinases (IKK) complex as critical controllers of HM apoptosis. Inhibition of NF-kB/IKK activity is associated with elevated rates of HM apoptosis and rapid recovery from fibrosis. The overarching aim of the current proposal is to determine the role played by the IKKbeta component of the IKK complex and to develop a highly specific inhibitor of IKKbeta action in HM. The role of IKKbeta in both the progressive and regressive phases of fibrosis will be investigated using a mouse in which the IKKbeta gene can be deleted at will and selectively in fibroblasts and myofibroblasts. Mice in which the IKKbeta allele is flanked by loxP sites will be crossed with mice in which Cre is under the transcriptional control of the alpha2 (I) collagen enhancer and post-translational control by Tamoxifen providing regulated and cell-specific knockout of IKKbeta expression. Importantly, this system will enable the fibrogenic role of IKKbeta to be studied independently from its pro-inflammatory function in the injured liver. The mice will be used in models of fibrogenesis (CCl4 injury) and recovery from fibrosis (following chronic injury with CCl4). Histological (Sirius Red for collagen I/III and alphaSMA for numbers of HM) and biochemical (qRT-PCR for fibrogenic markers, hydroxyproline and MMP activity assays). We anticipate that loss of IKKbeta will be associated with prevention of fibrosis and improved rates of recovery from fibrosis. Work in the second part of the proposal will address the way in which IKKbeta regulates NF-kB which from previous work and pilot data appears to operate via phosphorylation of the p65 subunit of NF-kB. In addition a specific peptide inhibitor of IKKbeta-mediated p65 phosphorylation will be tested for its ability to inhibit NF-kB, promote apoptosis and stimulate recovery from fibrosis.
4 schema:endDate 2010-02-28T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.14105.31
6 schema:identifier N8c6b8edc724747b6920b432e4891409e
7 N9b983a1ce2004038a4ee1c99bedbc6aa
8 schema:inLanguage en
9 schema:keywords CCl4
10 CCl4 injury
11 Cre
12 HCV
13 HM apoptosis
14 Histological
15 IKK
16 IKK activity
17 IKK complex
18 IKKbeta
19 IKKbeta action
20 IKKbeta allele
21 IKKbeta component
22 IKKbeta expression
23 IKKbeta gene
24 IKKbeta inhibitors
25 MMP activity assays
26 Medical Research Council Press Offices
27 NF-kB
28 NF-kB activity
29 NF-kB.
30 Sirius Red
31 Southampton
32 University
33 Websites
34 ability
35 addition
36 aim
37 alcohol
38 alpha2
39 alphaSMA
40 alternative
41 anti-inflammatory drugs
42 apoptosis
43 applicant laboratory
44 applicants
45 autoimmune attack
46 cases recovery
47 cell-specific knockout
48 cells
49 chronic injury
50 cirrhosis
51 collagen I/III
52 collagen enhancer
53 colleagues
54 critical controller
55 current proposals
56 data
57 death
58 disease process
59 drugs
60 elevated rates
61 end stage
62 end-stage disease
63 enhanced rates
64 evidence
65 experimental fibrosis
66 experimental study
67 experiments
68 fibroblasts
69 fibrogenesis
70 fibrogenic markers
71 fibrogenic role
72 fibrosis
73 form
74 function
75 functional disorders
76 general public
77 grant income
78 healthy function
79 hepatic myofibroblasts
80 hepatitis C
81 hepatology clinic
82 high quality
83 hydroxyproline
84 important role
85 improved rates
86 inhibition
87 injured liver
88 injury
89 key molecules
90 likely benefit
91 liver
92 liver cirrhosis
93 liver disease
94 liver disease patients
95 liver fibrosis
96 liver tissue
97 loss
98 loxP sites
99 metabolic agents
100 mice
101 model
102 molecules
103 myofibroblasts
104 new hope
105 new paradigm
106 non-functional scar tissue
107 normal healthy tissue
108 number
109 only option
110 other laboratories
111 other liver cells
112 overarching aim
113 p65 phosphorylation
114 p65 subunit
115 patients
116 persistent injury
117 phosphorylation
118 pilot data
119 post-translational control
120 press releases
121 prevention
122 previous work
123 pro-inflammatory functions
124 process
125 production
126 progress
127 progression
128 progressive replacement
129 project
130 proposal
131 public lectures
132 publication
133 qRT-PCR
134 rapid recovery
135 rate
136 recent work
137 recovery
138 reduced severity
139 regression
140 regressive phase
141 removal
142 replacement
143 response
144 results
145 reversibility
146 role
147 scar
148 scar tissue
149 scientific journals
150 second part
151 several years
152 small number
153 specific inhibitor
154 specific peptide inhibitor
155 spontaneous regression
156 state
157 stimulation
158 study
159 survival factor
160 system
161 tamoxifen
162 target
163 technical summary
164 transcriptional control
165 transplantation
166 treatment
167 underlying cause
168 use
169 virus
170 way
171 wide variety
172 will
173 work
174 world
175 years
176 schema:name Function of IKKbeta in the progression and regression of liver fibrosis
177 schema:recipient N13805a925b714bae99d6a443c9543189
178 N94eacdf6fb4d416e8c2e7e675823424a
179 sg:person.01361723223.86
180 sg:person.0636317123.31
181 https://www.grid.ac/institutes/grid.1006.7
182 schema:sameAs https://app.dimensions.ai/details/grant/grant.2764772
183 schema:sdDatePublished 2019-03-07T11:33
184 schema:sdLicense https://scigraph.springernature.com/explorer/license/
185 schema:sdPublisher Nd6da63711ba946b2ac66c8ed048b92c0
186 schema:startDate 2007-03-01T00:00:00Z
187 schema:url http://gtr.rcuk.ac.uk/project/71B673FF-09A0-4580-B6ED-EACB128618C4
188 sgo:license sg:explorer/license/
189 sgo:sdDataset grants
190 rdf:type schema:MonetaryGrant
191 N13805a925b714bae99d6a443c9543189 schema:member sg:person.0636317123.31
192 schema:roleName Co-PI
193 rdf:type schema:Role
194 N37365371ff71465fbad3586110b4f268 schema:currency GBP
195 schema:value 259312
196 rdf:type schema:MonetaryAmount
197 N8c6b8edc724747b6920b432e4891409e schema:name dimensions_id
198 schema:value 2764772
199 rdf:type schema:PropertyValue
200 N94eacdf6fb4d416e8c2e7e675823424a schema:member sg:person.01361723223.86
201 schema:roleName PI
202 rdf:type schema:Role
203 N9b983a1ce2004038a4ee1c99bedbc6aa schema:name gtr_id
204 schema:value 71B673FF-09A0-4580-B6ED-EACB128618C4
205 rdf:type schema:PropertyValue
206 Nd6da63711ba946b2ac66c8ed048b92c0 schema:name Springer Nature - SN SciGraph project
207 rdf:type schema:Organization
208 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
209 rdf:type schema:DefinedTerm
210 sg:person.01361723223.86 schema:affiliation https://www.grid.ac/institutes/grid.1006.7
211 schema:familyName Mann
212 schema:givenName Derek
213 rdf:type schema:Person
214 sg:person.0636317123.31 schema:affiliation https://www.grid.ac/institutes/grid.1006.7
215 schema:familyName Mann
216 schema:givenName Jelena
217 rdf:type schema:Person
218 https://www.grid.ac/institutes/grid.1006.7 schema:name Newcastle University
219 rdf:type schema:Organization
220 https://www.grid.ac/institutes/grid.14105.31 schema:Organization
 




Preview window. Press ESC to close (or click here)


...